In his current role at ADVI Health, Dr Kolodziej supports innovative alternative payment programs, including the cancer care model and private payer initiatives, on behalf of life science organizations, payers and providers. providers around the world. Prior to ADVI Health, he joined Flatiron Health in July 2016 as National Medical Director, Managed Care Strategy, where he applied Flatiron’s core data and technology capabilities to facilitate practice transformation and success in alternative payment models. In 2013, Dr Kolodziej also served as Aetna’s National Medical Director, Oncology Solutions, leading Aetna’s Oncology Delivery Reform Pilot Projects. While at Aetna, he was the architect of the Aetna Oncology Medical Home program.
“We are honored that Dr Kolodziej is now part of our board of directors”, explained the President and CEO of LUNGevity Andrea Ferris. “Michael has dedicated his career to being a guiding force for cost-effective, patient-centered care in oncology. We look forward to his expertise and guidance elevating our work in the years to come.
“I have been working with LUNGevity for several years and am delighted to join their board of directors,” said Dr Kolodziej. “Lung cancer remains the most common cause of cancer death in the United States, and the work LUNGevity has done to represent patients has been essential in improving their outcomes, but much remains to be done.
Dr Kolodziej attended university and Washington University in Saint Louis, where he was appointed to Phi Beta Kappa and Alpha Omega Alpha. He trained in internal medicine and hematology-oncology at the University of Pennsylvania in Philadelphia cream.
About the LUNGevity Foundation
The LUNGevity Foundation is the leading national lung cancer organization focused on improving outcomes for people with lung cancer through research, education, policy initiatives and support and advocacy. ‘engagement of patients, survivors and caregivers. LUNGevity seeks to have an immediate impact on the quality of life and survival of all those affected by the disease, while promoting health equity by addressing disparities across the continuum of care. LUNGevity works tirelessly to advance research on early detection and more effective treatments, provide information and educational tools to empower patients and their caregivers, promote impactful public policy initiatives and amplify patient voices through advocacy. research and engagement. The organization provides an active community for patients and survivors – and those who help them live longer and better lives.
Comprehensive resources include a medically verified, patient-centric website, a toll-free helpline for support, the International Lung Cancer Survival Conference, and an easy-to-use interface. Clinical Trials Finder, among other tools. All of these programs are aimed at achieving our vision: a world where no one dies of lung cancer. The LUNGevity Foundation is proud to be a Four Star Charity Navigator organization.
Please visit www.LUNGevity.org to learn more.
About lung cancer in the United States
- About 1 in 16 Americans will be diagnosed with lung cancer in their lifetime
- More than 228,000 people in the United States will be diagnosed with lung cancer this year
- About 60% to 65% of all new lung cancer diagnoses are in people who have never smoked or are former smokers
- Lung cancer takes more lives than the three major cancers (colorectal, breast and prostate) combined
- Only 21% of all people diagnosed with lung cancer will survive 5 years or more, BUT if it is caught before it spreads, the chances of survival at 5 years improve dramatically
SOURCE LUNGevity Foundation